PXMD
PaxMedica, Inc., a clinical stage biopharmaceutical company, focuses on the development of anti-purinergic drug therapies (APT) for the treatment of disorders with intractable neurologic symptoms. The company's lead product candidate is PAX-101, an intravenous formulation of suramin for various indications, including autism spectrum disorder, myalgic encephalomyelitis/chronic fatigue syndrome, long COVID-19 syndrome, and human african trypanosomiasis. It is also involved in developing PAX-102, an intranasal formulation of suramin for neurologic indications. The company was formerly known as Purinix Pharmaceuticals LLC and changed its name to PaxMedica, Inc. in April 2020. PaxMedica, Inc. was incorporated in 2018 and is based in Tarrytown, New York. PaxMedica, Inc. operates as a subsidiary of Tardimed Sciences LLC.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2024 Q2 | -0.39 | $0 | -$1M |
| 2024 Q1 | -0.50 | $0 | -$3M |
| 2023 Q4 | -0.80 | $0 | -$3M |
| 2023 Q3 | -5.20 | $0 | -$2M |
| 2023 Q2 | -4.05 | $0 | -$3M |
| 2023 Q1 | -5.16 | $0 | -$3M |
| 2022 Q4 | -7.71 | $0 | -$3M |
| 2022 Q3 | -21.22 | $0 | -$2M |